<table class="drug-table data-table table table-condensed table-bordered"><tbody><tr id="identification"><th class="divider" colspan="2">Identification</th></tr><tr><th>Name</th><td><strong>Levorphanol</strong></td></tr><tr><th>Accession Number</th><td><strong>DB00854</strong>&#160; (APRD00764)</td></tr><tr><th>Type</th><td>small molecule</td></tr><tr><th>Groups</th><td>approved</td></tr><tr><th>Description</th><td><p>A narcotic analgesic that may be habit-forming. It is nearly as effective orally as by injection. [PubChem]</p></td></tr><tr><th>Structure</th><td><div class="structure"><a class="moldbi-thumbnail" href="http://structures.wishartlab.com/molecules/DB00854/image.png"><img alt="Thumb" src="http://structures.wishartlab.com/molecules/DB00854/thumb.png"></a></div><div class="structure-links"><div class="btn-group btn-group-xs"><a class="btn btn-default" href="/structures/structures/small_molecule_drugs/DB00854.mol">MOL</a><a class="btn btn-default" href="/structures/structures/small_molecule_drugs/DB00854.sdf">SDF</a><a class="btn btn-default" href="/structures/structures/small_molecule_drugs/DB00854.pdb">PDB</a><a class="btn btn-default" href="/structures/structures/small_molecule_drugs/DB00854.smiles">SMILES</a><a class="btn btn-default" href="/structures/structures/small_molecule_drugs/DB00854.inchi">InChI</a><a class="btn btn-info" href="/structures/structures/small_molecule_drugs/DB00854">View Structure</a></div></div></td></tr><tr><th>Synonyms</th><td class="data-table-container"><table class="table table-condensed table-striped datatable" id="synonyms"><thead><th>Synonym</th><th>Language</th><th>Code</th></thead><tbody><tr><td>Levorfanol</td><td>Spanish</td><td>INN</td></tr><tr><td>Levorfanolo</td><td>Italian</td><td>DCIT</td></tr><tr><td>L&#233;vorphanol</td><td>French</td><td>INN</td></tr><tr><td>Levorphanol</td><td>German</td><td>INN</td></tr><tr><td>Levorphanolum</td><td>Latin</td><td>INN</td></tr></tbody></table></td></tr><tr><th>Salts</th><td class="table-container"><table class="inner">
  <thead>
    <tr>
      <th>Name/CAS</th>
      <th>Structure</th>
      <th>Properties</th>
      <th></th>
    </tr>
  </thead>
  <tbody>
      <tr>
        <td>
          <strong>Levorphanol tartrate</strong>
          <div class="cas"></div>
        </td>
        <td><a class="moldbi-thumbnail" href="http://structures.wishartlab.com/molecules/DBSALT000935/image.png"><img alt="Thumb" src="http://structures.wishartlab.com/molecules/DBSALT000935/thumb.png"></a></td>
        <td>
            <span class="wishart wishart-not-available">Not applicable</span>
        </td>
        <td><a class="btn btn-default btn-xs" href="/salts/DBSALT000935">DBSALT000935</a></td>
      </tr>
  </tbody>
</table></td></tr><tr><th>Brand names</th><td class="data-table-container"><table class="table table-condensed table-striped datatable" id="brands"><thead><tr><th>Name</th><th>Company</th></tr></thead><tbody><tr><td>Aromarone</td><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><td>Cetarin</td><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><td>Lemoran</td><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><td>Levo-Dromoran</td><td>Valeant Pharmaceuticals International</td></tr></tbody></table></td></tr><tr><th>Brand mixtures</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>Categories</th><td><ul><li><a href="/mesh/analgesics-opioid">Analgesics, Opioid</a></li>
<li><a href="/mesh/narcotics">Narcotics</a></li></ul></td></tr><tr><th>CAS number</th><td>77-07-6</td></tr><tr><th>Weight</th><td>Average: 257.3706<br>Monoisotopic: 257.177964363</td></tr><tr><th>Chemical Formula</th><td>C<sub>17</sub>H<sub>23</sub>NO</td></tr><tr><th>InChI Key</th><td>JAQUASYNZVUNQP-USXIJHARSA-N</td></tr><tr><th>InChI</th><td><div class="wrap">InChI=1S/C17H23NO/c1-18-9-8-17-7-3-2-4-14(17)16(18)10-12-5-6-13(19)11-15(12)17/h5-6,11,14,16,19H,2-4,7-10H2,1H3/t14-,16+,17+/m0/s1</div></td></tr><tr><th>IUPAC Name</th><td><div class="wrap">(1R,9R,10R)-17-methyl-17-azatetracyclo[7.5.3.0^{1,10}.0^{2,7}]heptadeca-2(7),3,5-trien-4-ol</div></td></tr><tr><th>SMILES</th><td><div class="wrap">[H][C@@]12CCCC[C@@]11CCN(C)[C@@H]2CC2=C1C=C(O)C=C2</div></td></tr><tr><th>Mass Spec</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr id="taxonomy"><th class="divider" colspan="2">Taxonomy</th></tr><tr><th>Kingdom</th><td>Organic Compounds</td></tr><tr><th>Superclass</th><td>Alkaloids and Derivatives</td></tr><tr><th>Class</th><td>Morphinans</td></tr><tr><th>Subclass</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>Direct parent</th><td>Morphinans</td></tr><tr><th>Alternative parents</th><td>Benzylisoquinolines; Phenanthrenes and Derivatives; Tetralins; Phenols and Derivatives; Piperidines; Tertiary Amines; Enols; Polyamines</td></tr><tr><th>Substituents</th><td>phenanthrene; tetralin; phenol derivative; piperidine; benzene; tertiary amine; enol; polyamine; amine; organonitrogen compound</td></tr><tr><th>Classification description</th><td>This compound belongs to the morphinans. These are polycyclic compounds with a four-ring skeleton with three condensed six-member rings forming a partially hydrogenated phenanthrene moiety, one of which is aromatic while the two others are alicyclic.</td></tr><tr id="pharmacology"><th class="divider" colspan="2">Pharmacology</th></tr><tr><th>Indication</th><td>For the management of moderate to severe pain or as a preoperative medication where an opioid analgesic is appropriate</td></tr><tr><th>Pharmacodynamics</th><td>Levorphanol is a potent synthetic opioid analgesic indicated for the management of moderate to severe pain or as a preoperative medication where an opioid analgesic is appropriate. Levorphanol is similar to morphine in its actions, however it is up to 8 times more potent than morphine. Levorphanol produces a degree of respiratory depression similar to that produced by morphine at equianalgesic doses, and like many mu-opioid drugs, levorphanol produces euphoria or has a positive effect on mood in many individuals.</td></tr><tr><th>Mechanism of action</th><td>Like other mu-agonist opioids it is believed to act at receptors in the periventricular and periaqueductal gray matter in both the brain and spinal cord to alter the transmission and perception of pain.</td></tr><tr><th>Absorption</th><td>Levorphanol is well absorbed after PO administration with peak plasma concentrations occurring approximately 1 hour after dosing.</td></tr><tr><th>Volume of distribution</th><td><ul>
	<li>10 to 13 L/kg</li>
</ul></td></tr><tr><th>Protein binding</th><td>40%</td></tr><tr><th>Metabolism</th><td class="data-table-container"><p>Levorphanol is extensively metabolized in the liver and is eliminated as the glucuronide metabolite.</p></td></tr><tr><th>Route of elimination</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>Half life</th><td>11-16 hours</td></tr><tr><th>Clearance</th><td><ul>
	<li>0.78 to 1.1 L/kg/hr</li>
</ul></td></tr><tr><th>Toxicity</th><td>LD<sub>50</sub>=150 mg/kg (orally in rats). Signs of overdose include nausea, emesis, dizziness, respiratory depression, hypotension, urinary retention, cardiac arrhythmias, allergic reactions, skin rash, and uticaria.</td></tr><tr><th>Affected organisms</th><td><ul><li>Humans and other mammals</li></ul></td></tr><tr><th>Pathways</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>SNP Mediated Effects</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>SNP Mediated Adverse Drug Reactions</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr id="admet"><th class="divider" colspan="2">ADMET</th></tr><tr><th>Predicted ADMET features</th><td class="data-table-container"><table class="table table-condensed table-striped" id="predicted-admet">
  <thead>
    <tr>
      <th>Property</th>
      <th>Value</th>
      <th>Probability</th>
    </tr>
  </thead>
  <tbody>
      <tr>
        <td>Human Intestinal Absorption</td>
        <td>
              +
        </td>
        <td>0.9924</td>
      </tr>
      <tr>
        <td>Blood Brain Barrier</td>
        <td>
              +
        </td>
        <td>0.9953</td>
      </tr>
      <tr>
        <td>Caco-2 permeable</td>
        <td>
              +
        </td>
        <td>0.8767</td>
      </tr>
      <tr>
        <td>P-glycoprotein substrate</td>
        <td>
            Substrate
        </td>
        <td>0.8217</td>
      </tr>
      <tr>
        <td>P-glycoprotein inhibitor I</td>
        <td>
            Non-inhibitor
        </td>
        <td>0.7866</td>
      </tr>
      <tr>
        <td>P-glycoprotein inhibitor II</td>
        <td>
            Non-inhibitor
        </td>
        <td>0.935</td>
      </tr>
      <tr>
        <td>Renal organic cation transporter</td>
        <td>
            Inhibitor
        </td>
        <td>0.7666</td>
      </tr>
      <tr>
        <td>CYP450 2C9 substrate</td>
        <td>Non-substrate</td>
        <td>0.7467</td>
      </tr>
      <tr>
        <td>CYP450 2D6 substrate</td>
        <td>Substrate</td>
        <td>0.78</td>
      </tr>
      <tr>
        <td>CYP450 3A4 substrate</td>
        <td>Substrate</td>
        <td>0.7112</td>
      </tr>
      <tr>
        <td>CYP450 1A2 substrate</td>
        <td>Non-inhibitor</td>
        <td>0.6437</td>
      </tr>
      <tr>
        <td>CYP450 2C9 substrate</td>
        <td>Non-inhibitor</td>
        <td>0.9139</td>
      </tr>
      <tr>
        <td>CYP450 2D6 substrate</td>
        <td>Inhibitor</td>
        <td>0.7703</td>
      </tr>
      <tr>
        <td>CYP450 2C19 substrate</td>
        <td>Non-inhibitor</td>
        <td>0.8908</td>
      </tr>
      <tr>
        <td>CYP450 3A4 substrate</td>
        <td>Non-inhibitor</td>
        <td>0.8856</td>
      </tr>
      <tr>
        <td>CYP450 inhibitory promiscuity</td>
        <td>Low CYP Inhibitory Promiscuity</td>
        <td>0.9051</td>
      </tr>
      <tr>
        <td>Ames test</td>
        <td>
          Non AMES toxic 
        </td>
        <td>
            0.5661
        </td>
      </tr>
      <tr>
        <td>Carcinogenicity</td>
        <td>
          Non-carcinogens 
        </td>
        <td>
            0.9694
        </td>
      </tr>
      <tr>
        <td>Biodegradation</td>
        <td>
          Not ready biodegradable 
        </td>
        <td>
            0.9681
        </td>
      </tr>
      <tr>
        <td>Rat acute toxicity</td>
        <td>
          2.9455 
            LD50, mol/kg
        </td>
        <td>
            <span class="wishart wishart-not-available">Not applicable</span>
        </td>
      </tr>
      <tr>
        <td>hERG inhibition (predictor I)</td>
        <td>
          Weak inhibitor 
        </td>
        <td>
            0.6841
        </td>
      </tr>
      <tr>
        <td>hERG inhibition (predictor II)</td>
        <td>
          Non-inhibitor 
        </td>
        <td>
            0.5153
        </td>
      </tr>
  </tbody>
</table>
</td></tr><tr id="pharmacoeconomics"><th class="divider" colspan="2">Pharmacoeconomics</th></tr><tr><th>Manufacturers</th><td><ul><li>Valeant pharmaceuticals international</li>
<li>Roxane laboratories inc</li></ul></td></tr><tr><th>Packagers</th><td><ul><li><a href="http://www.cardinal.com">Cardinal Health</a></li>
<li><a href="http://www.legacypackaging.com">Legacy Pharmaceuticals Packaging LLC</a></li>
<li><a href="http://www.roxane.com">Roxane Labs</a></li>
<li><a href="http://www.valeant.com">Valeant Ltd.</a></li></ul></td></tr><tr><th>Dosage forms</th><td class="data-table-container"><table class="table table-condensed table-striped datatable" id="dosages"><thead><tr><th>Form</th><th>Route</th><th>Strength</th></tr></thead><tbody><tr><td>Injection, solution</td><td>Intramuscular</td><td></td></tr><tr><td>Injection, solution</td><td>Intravenous</td><td></td></tr><tr><td>Injection, solution</td><td>Subcutaneous</td><td></td></tr><tr><td>Tablet</td><td>Oral</td><td></td></tr></tbody></table></td></tr><tr id="spectra"><th class="divider" colspan="2">Spectra</th></tr><tr><th>Spectra</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr id="interactions"><th class="divider" colspan="2">Interactions</th></tr><tr><th>Drug Interactions</th><td class="data-table-container"><table class="table table-condensed table-striped" id="experimental-properties"><thead><tr><th>Drug</th><th style="width: 75%"></th></tr></thead><tbody><tr><td><a href="/drugs/DB06274">Alvimopan</a></td><td>Increases levels by receptor binding competition. Discontinue opioid administration at least 7 days prior to administrating Alvimopan. </td></tr><tr><td><a href="/drugs/DB06210">Eltrombopag</a></td><td>Increases levels of Levorphanol via metabolism decrease. UDP-glucuronosyltransferase inhibition with unclear significance. </td></tr><tr><td><a href="/drugs/DB00427">Triprolidine</a></td><td>The CNS depressants, Triprolidine and Levorphanol, may increase adverse/toxic effects due to additivity. Monitor for increased CNS depressant effects during concomitant therapy. </td></tr></tbody></table></td></tr><tr><th>Food Interactions</th><td><ul><li>Take without regard to meals. Avoid alcohol.</li></ul></td></tr></tbody></table>